Achieve Life Sciences, Inc. (ACHV)
USD 2.15
(2.63%)
USD 2.15
(2.63%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 19.37 Million USD | -35.37% |
| 2022 | 29.97 Million USD | -36.92% |
| 2021 | 47.51 Million USD | 17.91% |
| 2020 | 40.29 Million USD | 91.19% |
| 2019 | 21.07 Million USD | 10.45% |
| 2018 | 19.08 Million USD | 92.92% |
| 2017 | 9.89 Million USD | -63.99% |
| 2016 | 27.47 Million USD | -52.81% |
| 2015 | 58.2 Million USD | 3.41% |
| 2014 | 56.29 Million USD | 1.08% |
| 2013 | 55.68 Million USD | -32.1% |
| 2012 | 82.01 Million USD | 20.59% |
| 2011 | 68.01 Million USD | -24.36% |
| 2010 | 89.91 Million USD | 30.35% |
| 2009 | 68.98 Million USD | 366.4% |
| 2008 | 14.79 Million USD | -67.31% |
| 2007 | 45.24 Million USD | -33.94% |
| 2006 | 68.49 Million USD | 18.27% |
| 2005 | 57.91 Million USD | 156.59% |
| 2004 | 22.57 Million USD | 5.13% |
| 2003 | 21.46 Million USD | 19.7% |
| 2002 | 17.93 Million USD | 13.05% |
| 2001 | 15.86 Million USD | 10.86% |
| 2000 | 14.3 Million USD | -20.94% |
| 1999 | 18.1 Million USD | -3.72% |
| 1998 | 18.8 Million USD | -34.95% |
| 1997 | 28.9 Million USD | 7.84% |
| 1996 | 26.8 Million USD | 36.73% |
| 1995 | 19.6 Million USD | 512.5% |
| 1994 | 3.2 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 64.79 Million USD | -7.48% |
| 2024 Q1 | 70.02 Million USD | 261.51% |
| 2023 Q2 | 28.91 Million USD | 39.03% |
| 2023 Q3 | 24.33 Million USD | -15.83% |
| 2023 Q1 | 20.79 Million USD | -30.61% |
| 2023 FY | 19.37 Million USD | -35.37% |
| 2023 Q4 | 19.37 Million USD | -20.41% |
| 2022 Q4 | 29.97 Million USD | 26.34% |
| 2022 FY | 29.97 Million USD | -36.92% |
| 2022 Q1 | 40.61 Million USD | -14.53% |
| 2022 Q2 | 33.98 Million USD | -16.32% |
| 2022 Q3 | 23.72 Million USD | -30.2% |
| 2021 Q2 | 45.56 Million USD | 35.36% |
| 2021 Q4 | 47.51 Million USD | 25.71% |
| 2021 Q1 | 33.66 Million USD | -16.47% |
| 2021 FY | 47.51 Million USD | 17.91% |
| 2021 Q3 | 37.79 Million USD | -17.04% |
| 2020 Q4 | 40.29 Million USD | 45.92% |
| 2020 Q1 | 16.64 Million USD | -21.02% |
| 2020 FY | 40.29 Million USD | 91.19% |
| 2020 Q2 | 16.45 Million USD | -1.14% |
| 2020 Q3 | 27.61 Million USD | 67.8% |
| 2019 Q2 | 14.75 Million USD | 1.75% |
| 2019 Q3 | 11.49 Million USD | -22.11% |
| 2019 Q1 | 14.5 Million USD | -24.01% |
| 2019 Q4 | 21.07 Million USD | 83.41% |
| 2019 FY | 21.07 Million USD | 10.45% |
| 2018 Q2 | 19.22 Million USD | 127.19% |
| 2018 FY | 19.08 Million USD | 92.92% |
| 2018 Q4 | 19.08 Million USD | 11.34% |
| 2018 Q3 | 17.14 Million USD | -10.82% |
| 2018 Q1 | 8.46 Million USD | -14.48% |
| 2017 Q2 | 14.87 Million USD | -16.9% |
| 2017 Q1 | 17.9 Million USD | -34.83% |
| 2017 Q4 | 9.89 Million USD | -24.08% |
| 2017 Q3 | 13.02 Million USD | -12.43% |
| 2017 FY | 9.89 Million USD | -63.99% |
| 2016 Q4 | 27.47 Million USD | -21.68% |
| 2016 Q2 | 42.19 Million USD | -13.6% |
| 2016 Q3 | 35.07 Million USD | -16.88% |
| 2016 FY | 27.47 Million USD | -52.81% |
| 2016 Q1 | 48.84 Million USD | -16.09% |
| 2015 Q4 | 58.2 Million USD | -14.7% |
| 2015 Q1 | 46.38 Million USD | -17.6% |
| 2015 Q2 | 63.35 Million USD | 36.59% |
| 2015 Q3 | 68.23 Million USD | 7.7% |
| 2015 FY | 58.2 Million USD | 3.41% |
| 2014 Q4 | 56.29 Million USD | -10.15% |
| 2014 FY | 56.29 Million USD | 1.08% |
| 2014 Q3 | 62.65 Million USD | 25.98% |
| 2014 Q2 | 49.73 Million USD | -0.18% |
| 2014 Q1 | 49.82 Million USD | -10.53% |
| 2013 Q2 | 69.3 Million USD | -8.02% |
| 2013 Q3 | 61.63 Million USD | -11.07% |
| 2013 Q4 | 55.68 Million USD | -9.65% |
| 2013 FY | 55.68 Million USD | -32.1% |
| 2013 Q1 | 75.35 Million USD | -8.12% |
| 2012 FY | 82.01 Million USD | 20.59% |
| 2012 Q2 | 108.01 Million USD | -6.25% |
| 2012 Q3 | 97.17 Million USD | -10.04% |
| 2012 Q4 | 82.01 Million USD | -15.6% |
| 2012 Q1 | 115.22 Million USD | 69.41% |
| 2011 Q4 | 68.01 Million USD | -8.92% |
| 2011 FY | 68.01 Million USD | -24.36% |
| 2011 Q3 | 74.68 Million USD | -6.09% |
| 2011 Q2 | 79.52 Million USD | -6.0% |
| 2011 Q1 | 84.59 Million USD | -5.92% |
| 2010 Q4 | 89.91 Million USD | 88.22% |
| 2010 Q1 | 56.43 Million USD | -18.18% |
| 2010 Q2 | 51.14 Million USD | -9.38% |
| 2010 Q3 | 47.77 Million USD | -6.59% |
| 2010 FY | 89.91 Million USD | 30.35% |
| 2009 Q2 | 7.38 Million USD | -33.47% |
| 2009 FY | 68.98 Million USD | 366.4% |
| 2009 Q4 | 68.98 Million USD | 372.98% |
| 2009 Q3 | 14.58 Million USD | 97.53% |
| 2009 Q1 | 11.09 Million USD | -24.97% |
| 2008 Q3 | 20.24 Million USD | -39.44% |
| 2008 FY | 14.79 Million USD | -67.31% |
| 2008 Q1 | 39.38 Million USD | -12.96% |
| 2008 Q2 | 33.43 Million USD | -15.11% |
| 2008 Q4 | 14.79 Million USD | -26.96% |
| 2007 Q4 | 45.24 Million USD | -6.37% |
| 2007 FY | 45.24 Million USD | -33.94% |
| 2007 Q1 | 59.95 Million USD | -12.46% |
| 2007 Q2 | 52.63 Million USD | -12.21% |
| 2007 Q3 | 48.32 Million USD | -8.2% |
| 2006 FY | 68.49 Million USD | 18.27% |
| 2006 Q2 | 78.08 Million USD | 46.93% |
| 2006 Q4 | 68.49 Million USD | -5.01% |
| 2006 Q3 | 72.1 Million USD | -7.66% |
| 2006 Q1 | 53.14 Million USD | -8.23% |
| 2005 Q4 | 57.91 Million USD | 134.05% |
| 2005 FY | 57.91 Million USD | 156.59% |
| 2005 Q1 | 16.84 Million USD | -25.39% |
| 2005 Q2 | 12.85 Million USD | -23.69% |
| 2005 Q3 | 24.74 Million USD | 92.54% |
| 2004 Q4 | 22.57 Million USD | -15.9% |
| 2004 Q1 | 18.66 Million USD | -13.05% |
| 2004 Q2 | 30.5 Million USD | 63.42% |
| 2004 Q3 | 26.83 Million USD | -12.02% |
| 2004 FY | 22.57 Million USD | 5.13% |
| 2003 Q3 | 23.89 Million USD | 84.07% |
| 2003 Q4 | 21.46 Million USD | -10.15% |
| 2003 Q2 | 12.97 Million USD | -16.96% |
| 2003 Q1 | 15.63 Million USD | -12.84% |
| 2003 FY | 21.46 Million USD | 19.7% |
| 2002 Q4 | 17.93 Million USD | -14.37% |
| 2002 Q3 | 20.94 Million USD | -12.0% |
| 2002 Q1 | 26.28 Million USD | 65.68% |
| 2002 FY | 17.93 Million USD | 13.05% |
| 2002 Q2 | 23.8 Million USD | -9.45% |
| 2001 Q3 | 17.17 Million USD | 34.23% |
| 2001 FY | 15.86 Million USD | 10.86% |
| 2001 Q4 | 15.86 Million USD | -7.66% |
| 2001 Q1 | 13.72 Million USD | -4.06% |
| 2001 Q2 | 12.79 Million USD | -6.78% |
| 2000 Q3 | 16.25 Million USD | -11.38% |
| 2000 Q1 | 16.31 Million USD | -9.85% |
| 2000 FY | 14.3 Million USD | -20.94% |
| 2000 Q2 | 18.34 Million USD | 12.44% |
| 2000 Q4 | 14.3 Million USD | -11.99% |
| 1999 Q3 | 16.3 Million USD | 13.19% |
| 1999 Q4 | 18.1 Million USD | 11.04% |
| 1999 Q1 | 17.2 Million USD | -8.51% |
| 1999 FY | 18.1 Million USD | -3.72% |
| 1999 Q2 | 14.4 Million USD | -16.28% |
| 1998 Q1 | 26 Million USD | -10.03% |
| 1998 Q4 | 18.8 Million USD | -15.32% |
| 1998 FY | 18.8 Million USD | -34.95% |
| 1998 Q2 | 23.6 Million USD | -9.23% |
| 1998 Q3 | 22.2 Million USD | -5.93% |
| 1997 Q2 | 28.5 Million USD | 4.78% |
| 1997 Q3 | 27.8 Million USD | -2.46% |
| 1997 Q4 | 28.9 Million USD | 3.96% |
| 1997 FY | 28.9 Million USD | 7.84% |
| 1997 Q1 | 27.2 Million USD | 1.49% |
| 1996 Q4 | 26.8 Million USD | 14.04% |
| 1996 Q2 | 20.5 Million USD | 30.57% |
| 1996 Q3 | 23.5 Million USD | 14.63% |
| 1996 FY | 26.8 Million USD | 36.73% |
| 1996 Q1 | 15.7 Million USD | -19.9% |
| 1995 Q3 | 2.2 Million USD | 0.0% |
| 1995 FY | 19.6 Million USD | 512.5% |
| 1995 Q4 | 19.6 Million USD | 790.91% |
| 1994 Q4 | 3.2 Million USD | 0.0% |
| 1994 FY | 3.2 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Caribou Biosciences, Inc. | 440.96 Million USD | 95.607% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -33.532% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -134.431% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 65.831% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 95.319% |
| C4 Therapeutics, Inc. | 376.45 Million USD | 94.854% |
| Agenus Inc. | 313.91 Million USD | 93.829% |
| Fortress Biotech, Inc. | 167.52 Million USD | 88.437% |
| GlycoMimetics, Inc. | 45.31 Million USD | 57.254% |
| Novavax, Inc. | 1.85 Billion USD | 98.956% |
| Keros Therapeutics, Inc. | 370.02 Million USD | 94.765% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | 38.97% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 95.724% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 95.871% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | 91.986% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 99.494% |
| AlloVir, Inc. | 190.79 Million USD | 89.847% |
| Aptorum Group Limited | 20.64 Million USD | 6.149% |
| Ardelyx, Inc. | 297.57 Million USD | 93.49% |
| Bicycle Therapeutics plc | 595.34 Million USD | 96.746% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | 73.717% |
| Chimerix, Inc. | 212.77 Million USD | 90.896% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | 31.484% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 99.131% |
| Clearside Biomedical, Inc. | 34.01 Million USD | 43.057% |
| Precision BioSciences, Inc. | 159.78 Million USD | 87.877% |
| Dyadic International, Inc. | 8.21 Million USD | -135.679% |
| Elevation Oncology, Inc. | 89.09 Million USD | 78.257% |
| Fortress Biotech, Inc. | 167.52 Million USD | 88.437% |
| GT Biopharma, Inc. | 14.1 Million USD | -37.295% |
| Alkermes plc | 2.13 Billion USD | 99.093% |
| Immix Biopharma, Inc. | 19.92 Million USD | 2.781% |
| Innoviva, Inc. | 1.24 Billion USD | 98.442% |
| IO Biotech, Inc. | 150.71 Million USD | 87.148% |
| Jaguar Health, Inc. | 50.76 Million USD | 61.84% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 97.675% |
| ContextLogic Inc. | 423 Million USD | 95.421% |
| AbCellera Biologics Inc. | 1.48 Billion USD | 98.698% |
| Lantern Pharma Inc. | 43.64 Million USD | 55.62% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -212.335% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 97.47% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 96.976% |
| MEI Pharma, Inc. | 41.37 Million USD | 53.182% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | 90.969% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2.364% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | 88.666% |
| NextCure, Inc. | 129.41 Million USD | 85.032% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | 87.993% |
| ChromaDex Corporation | 54.96 Million USD | 64.757% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 97.017% |
| Incyte Corporation | 6.78 Billion USD | 99.714% |
| Opthea Limited | 188.79 Million USD | 89.739% |
| MiMedx Group, Inc. | 239.04 Million USD | 91.897% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | 40.03% |
| Aadi Bioscience, Inc. | 132.42 Million USD | 85.372% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -1610.979% |
| Vaxcyte, Inc. | 1.4 Billion USD | 98.624% |
| PDS Biotechnology Corporation | 59.39 Million USD | 67.383% |
| Pharming Group N.V. | 462.85 Million USD | 95.815% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | 49.92% |
| Onconetix, Inc. | 88.82 Million USD | 78.191% |
| Acelyrin, Inc. | 742.69 Million USD | 97.392% |
| PureTech Health plc | 693.97 Million USD | 97.209% |
| Pyxis Oncology, Inc. | 173.72 Million USD | 88.85% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 96.918% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -274.703% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2.364% |
| ESSA Pharma Inc. | 149.12 Million USD | 87.01% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | 83.475% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | 64.093% |
| Seer, Inc. | 436.26 Million USD | 95.56% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 88.283% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -202.53% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | 57.226% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -194.101% |
| Summit Therapeutics Inc. | 202.94 Million USD | 90.455% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | 73.955% |
| Senti Biosciences, Inc. | 119.48 Million USD | 83.788% |
| ImmuCell Corporation | 43.8 Million USD | 55.782% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | 88.482% |
| Janux Therapeutics, Inc. | 380.4 Million USD | 94.908% |
| Precigen, Inc. | 151.04 Million USD | 87.175% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | 61.791% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | 47.26% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | 91.517% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 94.316% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -305.78% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 95.903% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | 76.26% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | 84.334% |
| VYNE Therapeutics Inc. | 97.68 Million USD | 80.17% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 40.224% |
| Wave Life Sciences Ltd. | 274.94 Million USD | 92.955% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 96.173% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -91.697% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | 93.709% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 95.895% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | 79.655% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -2967.031% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 96.58% |
| Aptose Biosciences Inc. | 12.92 Million USD | -49.901% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | 12.405% |
| Soligenix, Inc. | 9.79 Million USD | -97.717% |
| Century Therapeutics, Inc. | 360.69 Million USD | 94.629% |
| Kura Oncology, Inc. | 448.93 Million USD | 95.685% |
| TScan Therapeutics, Inc. | 272.14 Million USD | 92.882% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -12.003% |
| Ocean Biomedical, Inc. | 110.91 Million USD | 82.535% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | 90.558% |
| Autolus Therapeutics plc | 375.38 Million USD | 94.84% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | 92.302% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | 94.546% |
| Eterna Therapeutics Inc. | 49.13 Million USD | 60.574% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 97.07% |
| GRI Bio, Inc. | 2.95 Million USD | -555.311% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -82.655% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | 88.64% |
| IGM Biosciences, Inc. | 423.41 Million USD | 95.425% |
| INmune Bio, Inc. | 57 Million USD | 66.016% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 91.294% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 76.923% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 25.83% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -181.425% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | 74.25% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | 86.846% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 88.296% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 96.923% |
| Verastem, Inc. | 149.71 Million USD | 87.062% |
| Abeona Therapeutics Inc. | 64 Million USD | 69.734% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 96.218% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | 87.459% |
| Histogen Inc. | 19.07 Million USD | -1.562% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | 14.477% |
| Surrozen, Inc. | 46.08 Million USD | 57.962% |
| Organovo Holdings, Inc. | 6.34 Million USD | -205.103% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -349.587% |
| Ovid Therapeutics Inc. | 144.02 Million USD | 86.55% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -64.133% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | 74.264% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -127.379% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | 94.663% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -7.055% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 95.489% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -53.595% |
| Apollomics, Inc. | 55.38 Million USD | 65.026% |
| Amarin Corporation plc | 831.68 Million USD | 97.671% |
| Mesoblast Limited | 669.15 Million USD | 97.105% |
| Turnstone Biologics Corp. | 112.81 Million USD | 82.829% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 96.636% |
| Synaptogenix, Inc. | 31.11 Million USD | 37.741% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -58.987% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 96.466% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -229.873% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -163.725% |
| Exelixis, Inc. | 2.94 Billion USD | 99.342% |
| Better Therapeutics, Inc. | 22.94 Million USD | 15.569% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | 94.686% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 97.544% |
| NLS Pharmaceutics AG | 1.84 Million USD | -948.986% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -142.786% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -31.82% |
| Gritstone bio, Inc. | 177.76 Million USD | 89.103% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 79.691% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -8.446% |
| Avid Bioservices, Inc. | 336.55 Million USD | 94.244% |
| Insmed Incorporated | 1.32 Billion USD | 98.543% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -101.187% |
| MediWound Ltd. | 66.45 Million USD | 70.853% |
| OmniAb, Inc. | 401.98 Million USD | 95.181% |
| Alector, Inc. | 621.82 Million USD | 96.885% |
| Seres Therapeutics, Inc. | 358.6 Million USD | 94.598% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -260.19% |
| Zai Lab Limited | 1.03 Billion USD | 98.131% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 95.951% |
| Aura Biosciences, Inc. | 255.07 Million USD | 92.406% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 97.417% |
| Immunic, Inc. | 54.29 Million USD | 64.325% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | 92.724% |
| Veracyte, Inc. | 1.13 Billion USD | 98.298% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -63.845% |
| FibroGen, Inc. | 423.52 Million USD | 95.426% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -451.409% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -308.964% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -256.775% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 99.83% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -120.0% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 96.256% |
| TG Therapeutics, Inc. | 329.58 Million USD | 94.123% |
| Galecto, Inc. | 38.22 Million USD | 49.326% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 32.449% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 99.555% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | 91.771% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | 22.023% |
| XBiotech Inc. | 227.24 Million USD | 91.476% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | 79.691% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | 86.416% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | 93.225% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | 84.851% |
| Theravance Biopharma, Inc. | 381.99 Million USD | 94.929% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 98.701% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | 94.691% |
| Vaxxinity, Inc. | 44.35 Million USD | 56.325% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 96.253% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -4.093% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | 93.65% |
| NexImmune, Inc. | 8.59 Million USD | -125.403% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -80.781% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -13.1% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.941% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | 12.551% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -4838.243% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | 88.824% |
| Ainos, Inc. | 31.84 Million USD | 39.165% |
| Pluri Inc. | 39.52 Million USD | 50.993% |
| Prothena Corporation plc | 696.38 Million USD | 97.218% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | 93.146% |
| Celularity Inc. | 143.88 Million USD | 86.538% |
| Rallybio Corporation | 115.62 Million USD | 83.246% |
| Cue Biopharma, Inc. | 61.53 Million USD | 68.518% |
| MeiraGTx Holdings plc | 458.16 Million USD | 95.772% |
| Omeros Corporation | 378.26 Million USD | 94.879% |
| Humacyte, Inc. | 128.22 Million USD | 84.893% |
| Immunocore Holdings plc | 597 Million USD | 96.755% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | 38.031% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | 71.734% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 98.154% |
| CalciMedica, Inc. | 12.18 Million USD | -58.974% |
| Cabaletta Bio, Inc. | 253.65 Million USD | 92.363% |
| Scholar Rock Holding Corporation | 311.03 Million USD | 93.772% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 96.573% |
| Pulmatrix, Inc. | 33.95 Million USD | 42.956% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | 28.641% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | 86.248% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 98.511% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | 85.121% |
| Cytokinetics, Incorporated | 824.31 Million USD | 97.65% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 8.294% |
| Nutriband Inc. | 7.51 Million USD | -157.691% |
| Protara Therapeutics, Inc. | 78.95 Million USD | 75.465% |
| Vor Biopharma Inc. | 209.82 Million USD | 90.768% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 99.732% |
| Evogene Ltd. | 51.1 Million USD | 62.093% |
| ProKidney Corp. | 420.55 Million USD | 95.394% |
| Applied Therapeutics, Inc. | 54.83 Million USD | 64.673% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -103.471% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 96.455% |
| CorMedix Inc. | 82.05 Million USD | 76.394% |
| BioLineRx Ltd. | 63.92 Million USD | 69.697% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 95.188% |
| Galectin Therapeutics Inc. | 28.2 Million USD | 31.309% |
| Atai Life Sciences N.V. | 293.47 Million USD | 93.4% |
| Renovaro Biosciences Inc. | 163.12 Million USD | 88.125% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | 84.797% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 96.553% |
| Sagimet Biosciences Inc. | 96.71 Million USD | 79.972% |
| MediciNova, Inc. | 66.26 Million USD | 70.77% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | 77.974% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -334.097% |
| GeoVax Labs, Inc. | 9.28 Million USD | -108.667% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 96.707% |
| Biomea Fusion, Inc. | 199.92 Million USD | 90.311% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 98.982% |
| Mereo BioPharma Group plc | 66.49 Million USD | 70.87% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 96.007% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 96.839% |
| Absci Corporation | 234.48 Million USD | 91.739% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -164.812% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | 94.301% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | 88.266% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 96.32% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | 93.024% |
| Allakos Inc. | 243.61 Million USD | 92.048% |
| Imunon, Inc. | 21.91 Million USD | 11.621% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | 92.483% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 96.883% |
| BioAtla, Inc. | 119.65 Million USD | 83.811% |
| NLS Pharmaceutics AG | 1.84 Million USD | -948.986% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -501.584% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 96.987% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | 79.808% |
| XOMA Corporation | 234.3 Million USD | 91.732% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | 91.244% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 84.607% |
| aTyr Pharma, Inc. | 122.06 Million USD | 84.131% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | 87.414% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 96.662% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 96.05% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | 82.465% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -27.798% |
| Akari Therapeutics, Plc | 4.35 Million USD | -344.799% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -13.697% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 98.882% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -528.116% |
| UroGen Pharma Ltd. | 178.31 Million USD | 89.136% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 95.885% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -3385.78% |
| Orgenesis Inc. | 14.55 Million USD | -33.116% |
| Entera Bio Ltd. | 11.76 Million USD | -64.649% |
| GH Research PLC | 226.3 Million USD | 91.44% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | 64.583% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | 81.97% |
| Xencor, Inc. | 952.69 Million USD | 97.967% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -148.864% |
| Replimune Group, Inc. | 487.72 Million USD | 96.028% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -140.005% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 97.013% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -528.116% |
| Portage Biotech Inc. | 7.77 Million USD | -149.017% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -334.097% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | 93.005% |
| OncoCyte Corporation | 74.89 Million USD | 74.135% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -852.712% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -234.754% |
| Purple Biotech Ltd. | 44.3 Million USD | 56.275% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | 43.237% |
| scPharmaceuticals Inc. | 94.47 Million USD | 79.497% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -7.349% |
| HilleVax, Inc. | 344.43 Million USD | 94.376% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -509.918% |
| Tharimmune, Inc. | 10.94 Million USD | -76.962% |
| Genprex, Inc. | 10.67 Million USD | -81.536% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 96.096% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | 79.875% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -698.475% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -365.041% |
| OKYO Pharma Limited | 1.54 Million USD | -1156.826% |
| Savara Inc. | 177.56 Million USD | 89.091% |
| Curis, Inc. | 77.28 Million USD | 74.935% |
| Daré Bioscience, Inc. | 21.28 Million USD | 8.98% |
| Carmell Therapeutics Corporation | 63.94 Million USD | 69.709% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -139.562% |
| BeiGene, Ltd. | 5.8 Billion USD | 99.666% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -59.183% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 99.073% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | 94.588% |
| Erasca, Inc. | 395.29 Million USD | 95.1% |
| bluebird bio, Inc. | 619.16 Million USD | 96.871% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -348.053% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 99.717% |
| DBV Technologies S.A. | 182.98 Million USD | 89.414% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -348.053% |
| Moderna, Inc. | 18.42 Billion USD | 99.895% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -6.335% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -67.193% |
| Molecular Templates, Inc. | 35.38 Million USD | 45.253% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | 85.99% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 97.545% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | 93.623% |
| Spruce Biosciences, Inc. | 103.94 Million USD | 81.364% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 95.84% |
| Cogent Biosciences, Inc. | 313.43 Million USD | 93.82% |
| MacroGenics, Inc. | 306.82 Million USD | 93.687% |
| RenovoRx, Inc. | 1.46 Million USD | -1221.351% |
| Adicet Bio, Inc. | 207.29 Million USD | 90.655% |
| Prime Medicine, Inc. | 193.85 Million USD | 90.007% |
| Aditxt, Inc. | 44.57 Million USD | 56.546% |
| Adagene Inc. | 115.72 Million USD | 83.262% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -334.894% |
| Quantum-Si incorporated | 298.25 Million USD | 93.505% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 98.698% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -151.274% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | 94.486% |
| SciSparc Ltd. | 11.18 Million USD | -73.234% |
| Vericel Corporation | 353.65 Million USD | 94.523% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -58.615% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | 65.956% |
| Generation Bio Co. | 374.75 Million USD | 94.831% |
| Astria Therapeutics, Inc. | 254.66 Million USD | 92.394% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | 87.784% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | 94.325% |
| Invivyd, Inc. | 229.18 Million USD | 91.548% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 97.705% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -59.179% |
| Spero Therapeutics, Inc. | 182.39 Million USD | 89.379% |
| Artelo Biosciences, Inc. | 20.42 Million USD | 5.156% |
| 2seventy bio, Inc. | 565.42 Million USD | 96.574% |
| ADMA Biologics, Inc. | 329.18 Million USD | 94.115% |
| Clene Inc. | 52.34 Million USD | 62.991% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | 67.019% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | 85.087% |
| GeoVax Labs, Inc. | 9.28 Million USD | -108.667% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 97.037% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | 81.304% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | 85.143% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | 80.143% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 72.716% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | 92.014% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 99.012% |
| Evaxion Biotech A/S | 12.88 Million USD | -50.295% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | 92.315% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 97.426% |
| Trevena, Inc. | 40.6 Million USD | 52.294% |
| Surrozen, Inc. | 46.08 Million USD | 57.962% |
| Tyra Biosciences, Inc. | 225.85 Million USD | 91.423% |
| Cingulate Inc. | 3.49 Million USD | -454.815% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -16.489% |
| Unity Biotechnology, Inc. | 65.69 Million USD | 70.511% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -65.782% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | 92.786% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 97.414% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | 84.613% |
| Clearmind Medicine Inc. | 4.32 Million USD | -347.948% |
| Kronos Bio, Inc. | 213.27 Million USD | 90.918% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | 87.877% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -126.281% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 94.743% |
| Statera Biopharma, Inc. | 21.16 Million USD | 8.497% |
| ImmunityBio, Inc. | 504.45 Million USD | 96.16% |
| Korro Bio, Inc. | 221.66 Million USD | 91.261% |
| Kineta, Inc. | 10.28 Million USD | -88.416% |
| BioVie Inc. | 25.2 Million USD | 23.156% |
| Codexis, Inc. | 136.56 Million USD | 85.815% |
| Celularity Inc. | 143.88 Million USD | 86.538% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 96.951% |
| Celcuity Inc. | 191.21 Million USD | 89.87% |
| Virax Biolabs Group Limited | 5.48 Million USD | -253.23% |
| Cibus, Inc. | 544.41 Million USD | 96.442% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | 84.613% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 5.71% |
| IN8bio, Inc. | 33.7 Million USD | 42.535% |
| Kodiak Sciences Inc. | 479.37 Million USD | 95.959% |
| Annexon, Inc. | 297.67 Million USD | 93.493% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | 88.804% |
| Assembly Biosciences, Inc. | 137.46 Million USD | 85.909% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | 7.726% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 99.352% |
| Eyenovia, Inc. | 28.77 Million USD | 32.691% |
| Puma Biotechnology, Inc. | 230.52 Million USD | 91.597% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -168.148% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | 68.206% |
| Arcellx, Inc. | 825.13 Million USD | 97.652% |
| Cardiff Oncology, Inc. | 81.63 Million USD | 76.272% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 95.81% |
| Regulus Therapeutics Inc. | 30.75 Million USD | 37.005% |
| Moolec Science SA | 24.05 Million USD | 19.46% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | 93.754% |
| Geron Corporation | 394.07 Million USD | 95.084% |
| LAVA Therapeutics N.V. | 101.71 Million USD | 80.955% |
| Royalty Pharma plc | 16.38 Billion USD | 99.882% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 96.744% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -176.934% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -61.058% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | 91.431% |
| Humacyte, Inc. | 128.22 Million USD | 84.893% |
| Structure Therapeutics Inc. | 482.01 Million USD | 95.981% |
| 89bio, Inc. | 596.26 Million USD | 96.751% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | 92.318% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -947.081% |
| Genelux Corporation | 27.89 Million USD | 30.552% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | 78.333% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | 91.557% |
| Notable Labs, Ltd. | 19.54 Million USD | 0.87% |
| Liquidia Corporation | 120.43 Million USD | 83.915% |
| Mustang Bio, Inc. | 17.74 Million USD | -9.182% |
| Immunovant, Inc. | 666.71 Million USD | 97.095% |
| Quantum-Si incorporated | 298.25 Million USD | 93.505% |
| Arbutus Biopharma Corporation | 144.4 Million USD | 86.585% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | 64.234% |
| Vera Therapeutics, Inc. | 175.54 Million USD | 88.965% |
| Acasti Pharma Inc. | 73.3 Million USD | 73.573% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -325.523% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | 25.83% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 97.992% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -273.243% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | 14.969% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | 62.461% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | 89.279% |
| PepGen Inc. | 143.05 Million USD | 86.459% |
| Moleculin Biotech, Inc. | 38.21 Million USD | 49.313% |
| United Therapeutics Corporation | 7.16 Billion USD | 99.73% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -0.97% |
| Solid Biosciences Inc. | 164.93 Million USD | 88.256% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -229.873% |
| Immuneering Corporation | 102.58 Million USD | 81.117% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -349.587% |
| Silo Pharma, Inc. | 7.74 Million USD | -150.073% |
| Belite Bio, Inc | 94.64 Million USD | 79.532% |
| XOMA Corporation | 234.3 Million USD | 91.732% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | 91.693% |
| Bionomics Limited | 27.64 Million USD | 29.94% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 95.174% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 81.962% |
| uniQure N.V. | 831.68 Million USD | 97.671% |
| Cassava Sciences, Inc. | 151.66 Million USD | 87.228% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -334.894% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | 92.927% |
| Forte Biosciences, Inc. | 38.98 Million USD | 50.305% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -375.582% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | 47.406% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -168.148% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -451.409% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -63.869% |
| Altimmune, Inc. | 210.64 Million USD | 90.804% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 97.51% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | 81.962% |
| Compugen Ltd. | 121.33 Million USD | 84.035% |
| Peak Bio, Inc. | 2.59 Million USD | -646.067% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | 88.759% |
| Benitec Biopharma Inc. | 52.21 Million USD | 62.898% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | 94.334% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | 44.293% |
| Zura Bio Limited | 100.84 Million USD | 80.791% |
| PolyPid Ltd. | 15.37 Million USD | -26.015% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | 83.761% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | 44.293% |
| Instil Bio, Inc. | 325.63 Million USD | 94.051% |
| argenx SE | 4.54 Billion USD | 99.574% |
| Immunome, Inc. | 148.54 Million USD | 86.959% |
| Compass Therapeutics, Inc. | 156.87 Million USD | 87.652% |
| Verona Pharma plc | 308.12 Million USD | 93.713% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | 77.724% |
| Shattuck Labs, Inc. | 159.56 Million USD | 87.86% |
| CervoMed Inc. | 9.97 Million USD | -94.244% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | 89.721% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -70.1% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | 89.203% |
| Moolec Science SA | 24.05 Million USD | 19.46% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -216.65% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | 88.799% |
| AnaptysBio, Inc. | 452.38 Million USD | 95.718% |
| Design Therapeutics, Inc. | 289.64 Million USD | 93.312% |
| Leap Therapeutics, Inc. | 72.82 Million USD | 73.401% |
| NeurAxis, Inc. | 509.49 Thousand USD | -3701.978% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -257.53% |
| Lumos Pharma, Inc. | 40.63 Million USD | 52.333% |
| Achilles Therapeutics plc | 161.45 Million USD | 88.002% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | 77.724% |
| 180 Life Sciences Corp. | 5.25 Million USD | -268.307% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | 72.495% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -126.281% |
| Nutriband Inc. | 7.51 Million USD | -157.691% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | 92.394% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | 90.281% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | 74.583% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | 66.553% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 96.321% |
| Palisade Bio, Inc. | 14.05 Million USD | -37.852% |
| Tourmaline Bio, Inc. | 210.29 Million USD | 90.789% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 98.673% |
| Neurogene Inc. | 222.57 Million USD | 91.297% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 97.004% |
| AEON Biopharma, Inc. | 6.84 Million USD | -182.995% |
| Sesen Bio, Inc. | 189.17 Million USD | 89.76% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | 92.875% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -41.272% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 97.518% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | 92.745% |
| Athira Pharma, Inc. | 160.24 Million USD | 87.912% |
| Vaccinex, Inc. | 3.63 Million USD | -433.489% |
| HCW Biologics Inc. | 28.51 Million USD | 32.064% |
| XOMA Corporation | 234.3 Million USD | 91.732% |
| Nektar Therapeutics | 398.03 Million USD | 95.133% |
| Arvinas, Inc. | 1.3 Billion USD | 98.515% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -13.697% |
| Merus N.V. | 458.49 Million USD | 95.775% |
| Omega Therapeutics, Inc. | 204.36 Million USD | 90.521% |
| Quince Therapeutics, Inc. | 180.2 Million USD | 89.251% |
| Rezolute, Inc. | 132.73 Million USD | 85.406% |
| Clene Inc. | 52.34 Million USD | 62.991% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -29.799% |
| BeyondSpring Inc. | 24.8 Million USD | 21.916% |
| Synlogic, Inc. | 75.55 Million USD | 74.36% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -63.303% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -106.867% |
| Peak Bio, Inc. | 2.59 Million USD | -646.067% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | 88.92% |
| Krystal Biotech, Inc. | 818.35 Million USD | 97.633% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | 91.943% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 97.331% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -441.517% |
| MannKind Corporation | 475.19 Million USD | 95.924% |
| Ikena Oncology, Inc. | 192.09 Million USD | 89.916% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -44.841% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | 83.378% |
| Gossamer Bio, Inc. | 311.91 Million USD | 93.79% |
| CohBar, Inc. | 16.36 Million USD | -18.364% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | 44.911% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -164.812% |
| Legend Biotech Corporation | 1.84 Billion USD | 98.952% |
| Mural Oncology plc | 301.74 Million USD | 93.58% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 37.943% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -241.014% |
| Disc Medicine, Inc. | 367.99 Million USD | 94.736% |
| Champions Oncology, Inc. | 26.13 Million USD | 25.872% |
| REGENXBIO Inc. | 573.97 Million USD | 96.625% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -615.303% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 87.453% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -60.415% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | 94.303% |
| Vaxart, Inc. | 91.83 Million USD | 78.906% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | 67.663% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | 86.94% |
| Cellectis S.A. | 334.27 Million USD | 94.205% |
| Longeveron Inc. | 12.17 Million USD | -59.066% |
| Repare Therapeutics Inc. | 253.9 Million USD | 92.371% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 99.407% |
| Inozyme Pharma, Inc. | 200.84 Million USD | 90.355% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 99.073% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -1092.062% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | 93.025% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | 88.123% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | 86.038% |
| Anixa Biosciences, Inc. | 25.52 Million USD | 24.101% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.915% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 98.321% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -58.615% |
| Veru Inc. | 50.59 Million USD | 61.714% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | 57.476% |
| Cingulate Inc. | 3.49 Million USD | -454.815% |
| Passage Bio, Inc. | 150.54 Million USD | 87.133% |
| Context Therapeutics Inc. | 16.06 Million USD | -20.596% |
| Exicure, Inc. | 11.58 Million USD | -67.28% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | 94.849% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | 88.016% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -10.869% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | 94.178% |
| Nuvalent, Inc. | 732.38 Million USD | 97.355% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -29.623% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | 78.369% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -36.502% |
| OmniAb, Inc. | 401.98 Million USD | 95.181% |
| Anew Medical, Inc. | 19.45 Million USD | 0.437% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | 27.522% |
| Lipocine Inc. | 23 Million USD | 15.782% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | 86.144% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | 93.661% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | 76.923% |
| G1 Therapeutics, Inc. | 121.54 Million USD | 84.062% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -144.121% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 97.804% |
| Ocugen, Inc. | 64.54 Million USD | 69.989% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | 84.446% |
| Q32 Bio Inc. | 306.11 Million USD | 93.672% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -360.337% |
| Alumis Inc. Common Stock | 89.61 Million USD | 78.383% |
| Equillium, Inc. | 50.53 Million USD | 61.664% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | 74.239% |
| Coya Therapeutics, Inc. | 41.27 Million USD | 53.067% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -1038.899% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 25.898% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 69.94% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -419.732% |
| Dominari Holdings Inc. | 57.55 Million USD | 66.345% |
| Edesa Biotech, Inc. | 8.89 Million USD | -117.886% |
| vTv Therapeutics Inc. | 11.01 Million USD | -75.812% |
| Bio-Techne Corporation | 2.81 Billion USD | 99.311% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 97.933% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 97.613% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | 93.024% |
| Candel Therapeutics, Inc. | 41.7 Million USD | 53.549% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 97.098% |
| Nkarta, Inc. | 378.88 Million USD | 94.887% |
| BioCardia, Inc. | 2.98 Million USD | -548.51% |
| Iterum Therapeutics plc | 26.25 Million USD | 26.231% |